Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) have been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $12.33.

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a report on Monday, April 14th.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently bought and sold shares of TNGX. Barclays PLC lifted its stake in Tango Therapeutics by 78.3% during the 3rd quarter. Barclays PLC now owns 126,281 shares of the company’s stock valued at $972,000 after acquiring an additional 55,470 shares in the last quarter. Catalina Capital Group LLC bought a new position in Tango Therapeutics during the 4th quarter valued at $82,000. Congress Asset Management Co. lifted its stake in Tango Therapeutics by 9.0% during the 4th quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock valued at $704,000 after acquiring an additional 18,919 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Tango Therapeutics during the 4th quarter valued at $218,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Tango Therapeutics by 5.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company’s stock valued at $1,586,000 after purchasing an additional 26,192 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Stock Up 18.3%

Shares of TNGX opened at $1.52 on Friday. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $12.02. The business’s fifty day moving average is $1.46 and its 200 day moving average is $2.58. The stock has a market cap of $164.76 million, a P/E ratio of -1.29 and a beta of 1.02.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $5.39 million during the quarter, compared to the consensus estimate of $6.73 million. On average, analysts expect that Tango Therapeutics will post -1.19 EPS for the current year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.